UK life sciences firms struggle in post-Brexit war for EU talent

10 January 2018

Following the Brexit vote, the UK is already seeing problems in filling senior positions at life sciences companies, says DHR International, the global executive search firm.

DHR International says that, before Brexit, their average “slate” of candidates for senior roles at UK pharmaceutical companies was around 40% non-UK nationals. However, DHR would now expect to see just 15% non-UK candidates on average, as candidates are uncertain of the stability of a senior UK position following Brexit.

One area where recruiters for UK roles are looking to ‘poach’ senior staff is from the European Union’s medical evaluating body, the European Medicines Agency (EMA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK